bioAffinity Technologies, Inc. (BIAF): Results of Operations and Financial Condition
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and a
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectations for CyPath Lung commercialization based on quantified test volume, revenue, customer ordering growth, and the start of longitudinal trial enrollment, alongside the company’s cash position and expense increases.
Market read
Fresh 8-K disclosures show accelerating CyPath Lung utilization and revenue, plus ongoing investment and continued net losses, which can move BIAF sentiment and positioning.
What to watch
The filing notes R&D and clinical development cost increases (lab relocation and longitudinal study initiation) and does not disclose margins, cash burn beyond the quarter, or forward guidance, which can cap upside despite adoption metrics.
Background
bioAffinity Technologies filed an 8-K (Item 2.02) reporting Q2 2026 financial results and business highlights for its CyPath Lung diagnostic and pipeline expansion.
Ticker impact
bioAffinity reported Q2 2026 results with CyPath Lung test volume up 216% YoY and first-six-month testing revenue up 159% to about $835k.
Likely positive near-term bias if investors focus on accelerating CyPath Lung utilization, partially offset by continued net losses and rising operating costs.
The article is a first-time disclosure via an 8-K with quantified commercial growth, trial enrollment start, and a recent $3.2m gross-proceeds public offering, but it does not provide full guidance or profitability inflection.
Market effects
Adds datapoints on adoption velocity for noninvasive lung cancer diagnostics, which may influence sentiment toward early-stage biotech diagnostics with commercial traction.
Limited direct regional read-through; trial support references VA and military medical centers.
Primarily US-focused commercialization and clinical development; Mexico patent allowance is a minor international signal.
Counterpoint
Despite strong YoY growth rates, absolute revenue remains small and operating expenses are rising, so the market may discount the growth as insufficient for a durable path to profitability.
Key entities
- companybioAffinity Technologies, Inc.
Nasdaq-listed biotech reporting Q2 2026 results, CyPath Lung adoption metrics, trial enrollment progress, and a recent public offering.
- productCyPath Lung
Noninvasive lung diagnostic test whose test volume and revenue grew sharply in Q2 and first-half 2026.
- partnerPictor®, Inc.
Targeted proteomic platform company collaborating with bioAffinity on next-generation lung inflammation diagnostics.
- regulatorMexican Institute of Industrial Property
Notified allowance of a patent application related to defined antibodies and TCPP labeling in sputum.
